Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

D. Thaci; S. Piaserico; R. B. Warren; A. K. Gupta; W. Cantrell; Z. Draelos; P. Foley; A. Igarashi; R. G. Langley; A. Asahina; M. Young; M. Falqués; I. Pau-Charles; A. M. Mendelsohn; S. J. Rozzo; K. Reich

doi:10.1111/bjd.19866

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

D. Thaci, S. Piaserico, R. B. Warren, A. K. Gupta, W. Cantrell, Z. Draelos, P. Foley, A. Igarashi, R. G. Langley, A. Asahina, M. Young, M. Falqués, I. Pau-Charles, A. M. Mendelsohn, S. J. Rozzo, K. Reich

Research output: Contribution to journal › Article › peer-review

64 Citations (Scopus)

Original language	English
Pages (from-to)	323-334
Number of pages	12
Journal	British Journal of Dermatology
Volume	185
Issue number	2
DOIs	https://doi.org/10.1111/bjd.19866
Publication status	Published - Aug 2021
Externally published	Yes

ASJC Scopus Subject Areas

Dermatology

Access to Document

10.1111/bjd.19866

Fingerprint

Dive into the research topics of 'Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*'. Together they form a unique fingerprint.

Cite this

Thaci, D., Piaserico, S., Warren, R. B., Gupta, A. K., Cantrell, W., Draelos, Z., Foley, P., Igarashi, A., Langley, R. G., Asahina, A., Young, M., Falqués, M., Pau-Charles, I., Mendelsohn, A. M., Rozzo, S. J., & Reich, K. (2021). Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. British Journal of Dermatology, 185(2), 323-334. https://doi.org/10.1111/bjd.19866

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. / Thaci, D.; Piaserico, S.; Warren, R. B. et al.
In: British Journal of Dermatology, Vol. 185, No. 2, 08.2021, p. 323-334.

Research output: Contribution to journal › Article › peer-review

Thaci, D, Piaserico, S, Warren, RB, Gupta, AK, Cantrell, W, Draelos, Z, Foley, P, Igarashi, A, Langley, RG, Asahina, A, Young, M, Falqués, M, Pau-Charles, I, Mendelsohn, AM, Rozzo, SJ & Reich, K 2021, 'Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*', British Journal of Dermatology, vol. 185, no. 2, pp. 323-334. https://doi.org/10.1111/bjd.19866

@article{3bb1e0fde32646cfba59c9ffecc28e8e,

title = "Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*",

author = "D. Thaci and S. Piaserico and Warren, {R. B.} and Gupta, {A. K.} and W. Cantrell and Z. Draelos and P. Foley and A. Igarashi and Langley, {R. G.} and A. Asahina and M. Young and M. Falqu{\'e}s and I. Pau-Charles and Mendelsohn, {A. M.} and Rozzo, {S. J.} and K. Reich",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",

year = "2021",

month = aug,

doi = "10.1111/bjd.19866",

language = "English",

volume = "185",

pages = "323--334",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28

T2 - pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

AU - Thaci, D.

AU - Piaserico, S.

AU - Warren, R. B.

AU - Gupta, A. K.

AU - Cantrell, W.

AU - Draelos, Z.

AU - Foley, P.

AU - Igarashi, A.

AU - Langley, R. G.

AU - Asahina, A.

AU - Young, M.

AU - Falqués, M.

AU - Pau-Charles, I.

AU - Mendelsohn, A. M.

AU - Rozzo, S. J.

AU - Reich, K.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85105583577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105583577&partnerID=8YFLogxK

U2 - 10.1111/bjd.19866

DO - 10.1111/bjd.19866

M3 - Article

C2 - 33544883

AN - SCOPUS:85105583577

SN - 0007-0963

VL - 185

SP - 323

EP - 334

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 2

ER -

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this